

DAL
Sequence



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 18, 2003 Signature: Mary Jane DiPalma

(Mary Jane DiPalma)

Docket No.: GPCG-P01-017
(PATENT)

10
JM

3/4/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Varshavsky et al.

Application No.: 09/923917

Confirmation No.: 9016

Filed: August 6, 2001

Art Unit: 1645

For: SPLIT-UBIQUITIN BASED REPORTER
SYSTEMS AND METHODS OF THEIR USE

Examiner: Not Yet Assigned

PETITION TO WITHDRAW HOLDING OF ABANDONMENT

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

DEC 29 2003

TECH CENTER 1600/2900

Dear Sir:

In response to the Notice of Abandonment mailed by the Patent Office in this case on December 9, 2003, we offer the following evidence of a complete, timely-filed response by the Applicant to the outstanding Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (Notice) of May 3, 2002, and receipt of same in the United States Patent and Trademark Office (the Office). In view of the following, Applicants submit that the Notice of Abandonment was issued in error, and a withdrawal of the holding of abandonment is hereby requested. The submitted evidence includes:

1. A copy of the ~~papers printed out~~ from the electronic submission of the sequence listing on filed on ~~June 28, 2002~~ and
2. A copy of an electronic Acknowledgement Receipt received upon submission of the sequence listing.

Applicants reiterate that the Notice of Abandonment was issued in error, and a withdrawal of the holding of abandonment is hereby requested. No petition fee is due for a


Application No.: 09/923917

Docket No.: GPCG-P01-017

petition under 37 CFR 1.181. However, if there are any additional charges or credits, please apply them to Deposit Account No. 18-1945.

Dated: December 18, 2003

Respectfully submitted,

By 

David P. Halstead

Registration No.: 44,735

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant


 O I P E
 DEC 22 2003
 UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/923,917	08/06/2001	Alexander Varshavsky	GPCG-P01-017

CONFIRMATION NO. 9016

**ABANDONMENT/TERMINATION
LETTER**


OC000000011450807

 28120
 ROPES & GRAY LLP
 ONE INTERNATIONAL PLACE
 BOSTON, MA 02110-2624

Date Mailed: 12/09/2003

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 05/03/2002.

- No reply was received.

A petition to the Commissioner under 37 CFR 1.137 may be filed requesting that the application be revived.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(l); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL DELAY** must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Any questions concerning petitions to revive should be directed to the "Office of Petitions" at (703) 305-9282. Petitions should be mailed to: Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

RECEIVED

DEC 22 2003

*A copy of this notice **MUST** be returned with the reply.*

TECH CENTER 1600/2900

 Customer Service Center
 Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

AMINO ACID AND NUCLEOTIDE SEQUENCE LISTING FOR A PATENT APPLICATION

Electronic Version 1.0.1

Stylesheet Version 1.0.1



RECEIVED

DEC 29 2003

TECH CENTER 1600/2900

STATEMENT REGARDING SEQUENCE(S)

This is a request for filing the electronic copy of a sequence listing for a patent application under 37 C.F.R. 1.821-1.825.

This communication has an attached file which is the electronic copy of the amino acid and/or nucleotide sequence listing for the previously mentioned United States Patent Application.

The electronic copy submitted herewith is the Computer Readable Form (CRF), as required by 1.821(e).

Any applicable fees associated with the filing of the electronic copy have been paid.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter). It may be in addition to an original CRF, filed to comply with the sequence rules.

This submission in electronic form comprises only the CRF of 37 C.F.R. 1.821(e). Applicant is responsible for all additional requirements of amino acid and/or nucleotide sequence listing submissions as specified in 37 C.F.R. 1.821 - 1.825.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter), and/or is in addition to an original CRF filed to comply with the sequence rules. If not made to comply with an originally filed CRF, it is identical to the sequences disclosed in the application as originally filed and/or the paper copy of the Sequence Listing as originally filed.

Attachment Description:

CRF Biosequence



11
JM
3/4/04

TRANSMITTAL FORM

Electronic Version 1.0.3

Stylesheet Version: 1.0

Submission Type: BIO

Sequence Filing

Application Number: 09/923,917

Attorney Docket GPCG-P01-

Number:

RECEIVED

DEC 22 2003

TECH CENTER 1600/2900

Split-Ubiquitin Based Reporter Systems and Methods of Their Use

First Named Inventor: Alexander Varshavsky

SUBMITTED BY

Name: David P. Halstead
Registration Number: 44,735
Electronic Signature Mark: DYH Date Signed: 20020628

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

sequence-listing GPCG-P01-017SequenceListing.txt
biotechnology-listing-filing GPCG-P01-017Sequencebio.xml

I hereby certify that this correspondence is being transmitted to the Patent and Trademark Office on the following date. 2002-06-28

Name: David P. Halstead
Electronic Signature Mark: DYH

Comments:

Acknowledgment Receipt:

SUBMISSION TYPE: BIO Sequence Filing
APPLICATION NUMBER: 09923917
FIRST NAMED INVENTOR: Alexander Varshavsky
TITLE OF INVENTION: Split-Ubiquitin Based Reporter Systems and
Methods of Their Use
ATTORNEY DOCKET NUMBER: GPCG-P01-017



FILE LISTING:

transmittal	tranGPCG-P01-017Sequence.xml 6331 Bytes
sequence-listing	GPCG-P01-017SequenceListing.txt 3622 Bytes
biotechnology-listing-filing	GPCG-P01-017Sequencebio.xml 957 Bytes
biotechnology-listing-filing	u-bio.dtd 3619 Bytes
biotechnology-listing-filing	e-bioseq.xml 6067 Bytes

RECEIVED

DEC 23 2003

TECH CENTER 1600/2900

EFS ID: 16144

FILE SIZE: 15494 Bytes

TIMESTAMP: Fri Jun 28 18:35:54 EDT 2002

MESSAGE DIGEST: MhXlC7hp3kFomEhyE8d+w==

DIGITAL CERTIFICATE HOLDER NAME: cn=David P. Halstead, ou=Registered Attorneys

UPLOAD STATUS: You have successfully uploaded your submission to USPTO